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Abstract 
Mast cells (MCs) are metachromatic cells
that originate from multipotential hemopoietic
stem cells in the bone marrow. Two distinct
populations of MCs have been characterized:
mucosal MCs are tryptase-positive while mast
cells in skin contain tryptase and chymase. We
now  show  that  a  sub-population  of  MCs  is
highly  immunoreactive  for  thymosin  ʲ4,  as
revealed by immunohistochemical analyses of
normal skin, normal colon mucosa and salivary
gland tumors. Four consecutive serial sections
from each case were immunostained for thy-
mosin ʲ4 (Tʲ4), chymase, tryptase and stained
for  toluidine  blue.  In  skin  biopsies,  MCs
showed  a  comparable  immunoreactivity  for
Tʲ4,  chymase  and  tryptase.  In  normal  colon
mucosa  the  vast  majority  of    mucosal  MCs
expressed a strong cytoplasmic immunoreac-
tivity for tryptase and for Tʲ4, in the absence of
chymase reactivity. A robust expression of Tʲ4
was detected in tumor-infiltrating and peritu-
moral mast cells in salivary gland tumors and
breast ductal infiltrating carcinomas. Tumor-
infiltrating  MCs  also  showed  a  strong
immunoreactivity for chymase and tryptase. In
this paper, we first demonstrate that normal
dermal and mucosal mast cells exhibit strong
expression of thymosin ʲ4, which could be con-
sidered a new marker for the identification of
mast cells in skin biopsies as well as in human
tumors. The possible relationship between the
degree of Tʲ4 expression in tumor-infiltrating
mast cells and tumor behaviour warrants fur-
ther consideration in future investigations.
Introduction
Mast cells (MCs) are metachromatic cells
that originate from multipotential hemopoietic
stem cells in the bone marrow, and reside in
vascularized tissues where they play an impor-
tant role in the innate immune system.1 The
developmental pathways of mast cells within
different tissues appear to be different.2,3 The
observation of two distinct populations of mast
cells, i.e. mucosal mast cells characterized by
reactivity for chondroitin sulfate E proteogly-
can4 and  serosal  or  connective  tissue-type
mast  cells,  characterized  by  the  ability  to
sinthesize heparin5 led to the concept of mast
cell heterogeneity. Heterogeneity of mast cells
has been reported in different tissues both in
animals6 and in men.7 It has been demonstrat-
ed that mucosal mast cells differ from skin and
peritoneal mast cells, even in the expression of
two classes of proteases, one with trypsin-like
activity, called tryptase,8 and one with a chi-
motrypsin-like activity, called chymase,9 which
are among the major components of mast cell
granules.  In  humans,  these  proteinases  are
differentially expressed in mast cell subtypes:
mucosal MC are tryptase-positive, while mast
cells in skin contain tryptase and chymase.10
These MCs subtypes are designated MCt and
MCtc, respectively.  The specialization of mast
cells in different tissue sites has been hypoth-
esized  to  be  related  to  their  involvement  in
physiology and pathology, which is yet poorly
understood.11 MCs  can  also  be  stained  with
antibodies  against  c-kit.12 Histochemically,
mast cells may be easily revealed by toluidine
blue13 and by alcian blue-safranin14 stains. The
latter method is able to detect a higher number
of  mast  cells  than  toluidine  blue  staining.15
The fixation mode of tissue samples also influ-
ences the number of detected mast cells. It is
commonly accepted that Carnoy’s solution has
the best capacity to fix mast cell granules;16for-
malin is also good and allows appropriate his-
tochemistry  and  immunohistochemistry  for
MCs. The aim of this study is to propose the
introduction of thymosin ʲ4 (Tʲ4) as a new
marker for serosal, mucosal and tumor infil-
trating mast cells.
Materials and Methods
In order to test Tʲ4 immunoreactivity in the
different subtypes of human MCs, we exam-
ined 10 surgical specimens of normal skin con-
taining tryptase and chymase-positive serosal
MCs and 10 normal colon biopsies containing
tryptase-positive  mucosal  mast  cells.  Tʲ4
expression in tumor-infiltrating MCs was eval-
uated in 4 acinic cell carcinomas of salivary
glands and in 10 ductal infiltrating breast car-
cinomas. All 34 specimens were selected for
this  study  by  the  preliminary  demonstration
through toluidine-blue stain of metachromatic
granules-containing  MCs.  Positive  controls
included tonsil and reactive lymph nodes for
chymase and tryptase and for Tʲ4, respectively.
All samples were fixed in 10% formalin, paraf-
fin-embedded  and  routinely  processed.  The
immunohistochemical  technique  was  per-
formed in a DAKO autostainer. Paraffin sec-
tions  from  each  case  were  immunostained
with  the  policlonal  antibodies  against  thy-
mosin ʲ4 (Bachem-Peninsula Lab, San Carlos,
CA, USA; diluted 1:500), chymase (Novocastra,
Benton Lane, Newcastle, UK clone CC1, dilut-
ed  1:200)  and  tryptase  (Novocastra,  Benton
Lane,  Newcastle,  UK  clone  10D11,  diluted
1:300). A LSAB2 system-HRP kit (DAKO) was
used and the signal was visualized by the AEC
(3-amino-9-ethylcarbazole) substrate. All sam-
ples were also stained with the toluidine-blue
method.
Results
In  normal  skin,  dermal-serosal  mast  cells
showed substantially the same immunoreac-
tivity  for  chymase  (Figure  1c)  and  tryptase
(Figure  1b).  Moreover,  the  vast  majority  of
MCs  showed  reactivity  for  Tʲ4 (Figure  1a).
Toluidin blue stain confirmed the same reac-
tivity pattern (data not shown). 
In  normal  colon  mucosa,  a  different
immunoreactivity  pattern  was  detected.  The
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vast  majority  of  mucosal  MCs  expressed  a
strong  cytoplasmic  immunoreactivity  for  Tʲ4
(Figure 2a), which paralleled the immunoreac-
tivity for tryptase (Figure 2b). Mucosal colonic
MCs did not show any significant reactivity for
chymase (Figure 2c). 
In salivary gland tumors, peri- and intratu-
moral MCs showed a comparable immunoreac-
tivity  for  tryptase  (Figure  3b)  and  chymase
(Figure  3c).  Immunoreactivity  for  Tʲ4 was
found only in a subset of intratumoral mast
cells. (Figure 3a). 
In  breast  ductal  infiltrating  carcinomas,
tumor  infiltrating  and  peritumoral  MCs
showed  a  strong  reactivity  for    Tʲ4 and
tryptase;  immunoreactivity  for  chymase  was
detected only in a subset of MCs. The same
pattern  of  reactivity  was  found  in  MCs  sur-
rounding fibrocystic changes (Figure 4 a, b, c). 
Discussion
In this paper, we first demonstrate that nor-
mal dermal (serosal) and mucosal mast cells
exhibit strong expression of thymosin ʲ4. Tʲ4
expression was also found in tumor-infiltrat-
ing  and  peritumoral  mast  cells  in  salivary
gland  and  in  breast  tumors.  These  observa-
tions  extend  the  knowledge  regarding  the
immunophenotypic  profile  of  mast  cells  and
provide a useful new marker for the identifica-
tion  of  scattered  mast  cells  in  skin,  colon
mucosa as well as in tumors. The co-expres-
sion or separate expression of chymase and
tryptase  is  currently  used  as  a  specific
immunophenotypic profile to distinguish and
characterize, on tissue sections,  different sub-
types of mast cells.
10 According to our results,
Tʲ4could be considered as a marker for MCs in
this context, showing a degree of immunoreac-
tivity comparable in sensitivity to chymase and
tryptase.  In  this  study  Tʲ4 demonstrated  to
stain both serosal and mucosal MCs, parallel-
ing the sensitivity of tryptase in revealing tis-
sue MCs.
In addition, in this study we found a pattern
of reactivity for Tʲ4 which could be useful to
better characterize, on tissue sections, a new
subtype of  tumor infiltrating and peritumoral
MCs. In salivary gland tumors, Tʲ4 was detect-
ed only in a part of tumoral MCs, while reactiv-
ity for chymase and tryptase was found in all
MCs. A different protein reactivity pattern for
Tʲ4 was found in intra- and peri-tumoral MCs
in infiltrating ductal carcinoma of the breast.
In this contest, MCs showed the highest level
of reactivity for Tʲ4 and tryptase, whereas only
a minority of MCs were positive for chymase.
All together, these findings show a previously
unreported heterogeneity of tumor infiltrating
MCs, and introduce Tʲ4 as a useful marker, in
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Figure  2.  Normal  colon  mucosa:    original
magnification x400. (a) Immunohistochemi-
cal  detection  of  Tʲ4:  the  vast  majority  of
mucosal mast cells show a strong cytoplasmic
immunoreactivity. (b) Immunohistochemical
detection of tryptase shows cytoplasmic reac-
tivity in a minority of mucosal mast cells. (c)
Immunohistochemical detection of chymase
shows  cytoplasmic  reactivity  in  isolated
mucosal mast cells.
Figure 3. Acinic cell tumor of salivary gland:
original magnification x400. (a) Immuno-his-
tochemical detection of Tʲ4 shows an intense
cytoplasmic immunoreactivity in a minority
of  intratumoral  mast  cells.  (b)  Immunohi-
stochemical detection of tryptase shows cyto-
plasmic  immunoreactivity  in  intratumoral
mast cells. (c) Mast cells’ immunoreactivity for
chymase  shows  an  immunoreactive  pattern
comparable to that obtained with tryptase.
Figure 1. Normal skin. Original magnifica-
tion  x  250.  (a)  Immunohistochemical
detection of Tʲ4 shows cytoplasmic reactiv-
ity  in  scattered  dermal  mast  cells.  (b)
Immunohistochemical  detection  of
tryptase shows intense cytoplasmic immu-
oreactivity restricted to mast cells. (c) Mast
cells’ immunoreactivity for chymase shows
an immunoreactive pattern comparable to
that obtained with tryptase. [page 16] [European Journal of Histochemistry 2010; 54:e3]
association with  chymase and tryptase for the
identification of new subtypes of MCs. 
As far as the role of mast cells inside and
around malignant neoplasms is concerned, the
demonstration  of  strong  Tʲ4 expression  in
intratumoral  MCs  can  contribute  to  explain
their  function  as  effectors  of  the  innate
immune systems in the surveillance of tumor
progression. A number of experimental, bio-
chemical and microarray studies have already
documented  the  presence  of  a  high  level  of
expression of Tʲ4 in experimental and human
tumors.17,18 In particular, the role of Tʲ4 has
been analyzed in relation to tumor metasta-
sis,19-21 in human lung cancer,22 and  in human
colorectal cancer.23 Recently, an immunohisto-
chemical study on Tʲ4 expression in human
breast cancer revealed a low reactivity for the
peptide in cancer cells, while intense reactivi-
ty for Tʲ4 was detected in other cells of the
tumor microenvironment.24 On the basis of our
data, we may hypothesize that Tʲ4 - positive
peritumoral cells observed in that study could
be identified as MCs.
These data taken together, one may pose the
question whether the levels of Tʲ4 recorded in
extracts of tumor samples in previous studies
reflected levels in tumor cells or in the tumour
microenvironment. Our data give an answer to
this question, and clearly indicate mast cells as
partly responsible for the connection between
Tʲ4 and tumour progression.  The finding of a
strong reactivity for Tʲ4 in tumour-infiltrating
mast cells lays stress on the hypothesis that
Tʲ4 may constitute a local paracrine mediator
which could be relevant to our understanding
of cellular cross-talk within the tumor micro-
environment.24 Tʲ4 has been shown to exert
anti-inflammatory  and  cytoprotective  func-
tions,  by  suppressing  secretion  of  the  pro-
inflammatory cytokine, IL8 and by protecting
cells  against  apoptosis  induced  by  tumor
necrosis  factor-a.25 Moreover,  in  a  murine
corneal  model,  Tʲ4 potently  inhibited  neu-
trophil infiltration and significantly decreased
the  expression  of  pro-inflammatory  cyto-
kines.26 These  data  taken  together,  we  may
speculate that, because of its multifunctional
roles in protecting cells against apoptosis25 and
in  stimulating  neoangiogenesis,27-29 Tʲ4
released by mast cells in the tumor microenvi-
ronment could significantly contribute to can-
cer cell survival. As a consequence, Tʲ4-pro-
ducing MCs could represent a new molecular
target for antitumoral strategies30 in different
human tumors.
Finally, the expression of Tʲ4 in the cyto-
plasm of tumor-infiltrating mast cells reported
in this study extends our knowledge regarding
the  immunophenotypic  profile  of  mast  cells
and can significantly contribute to our under-
standing  of  cross-talk  between  cells  of  the
immune system and tumour cells. The possible
relationship between the degree of mast cell
infiltration and tumor behaviour warrants fur-
ther consideration in future investigations.
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